Veeva Systems Inc. $VEEV Shares Sold by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. decreased its position in Veeva Systems Inc. (NYSE:VEEV - Free Report) by 37.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,739 shares of the technology company's stock after selling 1,616 shares during the quarter. Atria Wealth Solutions Inc.'s holdings in Veeva Systems were worth $789,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. TFB Advisors LLC raised its stake in Veeva Systems by 1.2% in the 1st quarter. TFB Advisors LLC now owns 3,586 shares of the technology company's stock valued at $831,000 after purchasing an additional 44 shares during the last quarter. Triangle Securities Wealth Management raised its stake in Veeva Systems by 0.8% in the 2nd quarter. Triangle Securities Wealth Management now owns 5,782 shares of the technology company's stock valued at $1,665,000 after purchasing an additional 45 shares during the last quarter. Marks Group Wealth Management Inc raised its stake in Veeva Systems by 3.3% in the 1st quarter. Marks Group Wealth Management Inc now owns 1,427 shares of the technology company's stock valued at $331,000 after purchasing an additional 46 shares during the last quarter. Harbour Investments Inc. raised its stake in Veeva Systems by 7.6% in the 1st quarter. Harbour Investments Inc. now owns 789 shares of the technology company's stock valued at $183,000 after purchasing an additional 56 shares during the last quarter. Finally, Parallel Advisors LLC raised its stake in Veeva Systems by 4.7% in the 2nd quarter. Parallel Advisors LLC now owns 1,236 shares of the technology company's stock valued at $356,000 after purchasing an additional 56 shares during the last quarter. Institutional investors and hedge funds own 88.20% of the company's stock.

Analyst Ratings Changes

Several analysts have commented on the company. Mizuho lifted their price target on Veeva Systems from $295.00 to $325.00 and gave the company an "outperform" rating in a report on Friday, August 29th. UBS Group lifted their price target on Veeva Systems from $285.00 to $310.00 and gave the company a "neutral" rating in a report on Thursday, August 28th. William Blair restated an "outperform" rating on shares of Veeva Systems in a report on Friday. Truist Financial lifted their price target on Veeva Systems from $268.00 to $275.00 and gave the company a "hold" rating in a report on Thursday, August 28th. Finally, Wells Fargo & Company lifted their price target on Veeva Systems from $300.00 to $326.00 and gave the company an "overweight" rating in a report on Tuesday, August 26th. Seventeen research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $307.58.

Veeva Systems Stock Performance

Shares of NYSE:VEEV opened at $283.96 on Friday. Veeva Systems Inc. has a 1 year low of $201.54 and a 1 year high of $310.50. The stock has a market capitalization of $46.54 billion, a P/E ratio of 58.31, a PEG ratio of 2.19 and a beta of 0.98. The stock has a 50-day simple moving average of $283.44 and a 200-day simple moving average of $267.01.

Veeva Systems (NYSE:VEEV - Get Free Report) last issued its earnings results on Wednesday, August 27th. The technology company reported $1.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.90 by ($0.64). Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.The firm had revenue of $789.08 million for the quarter, compared to analysts' expectations of $768.49 million. During the same quarter in the previous year, the firm posted $1.62 EPS. The firm's revenue for the quarter was up 16.7% compared to the same quarter last year. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. Analysts predict that Veeva Systems Inc. will post 4.35 earnings per share for the current year.

Insider Transactions at Veeva Systems

In other news, SVP Jonathan Faddis sold 720 shares of the business's stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $298.12, for a total transaction of $214,646.40. Following the completion of the sale, the senior vice president owned 7,868 shares in the company, valued at approximately $2,345,608.16. The trade was a 8.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of the business's stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $306.62, for a total value of $1,839,720.00. Following the transaction, the insider directly owned 25,325 shares in the company, valued at $7,765,151.50. This trade represents a 19.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,665 shares of company stock worth $7,438,000. 10.30% of the stock is currently owned by company insiders.

Veeva Systems Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.